BRAVE-AA1 - a Phase 2 trial of 110 pts w/ Alopecia areata Rx w/ either PBO or baricitinib (1, 2, 4 mg); showed significantly greater improvement with Bari 2-mg (33.3%, P = .016) and 4-mg (51.9%, P = .001) versus placebo (3.6%). https://t.co/tzDeb4l60H